CBX7 and HMGA1b proteins act in opposite way on the regulation of the SPP1 gene expression

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2680-2692

  Sepe, Romina ^a   Formisano, Umberto ^a   Federico, Antonella ^a   Forzati, Floriana ^a   Bastos, André Uchimura ^a,b   D'Angelo, Daniela ^a   Cacciola, Nunzio Antonio ^a   Fusco, Alfredo ^a,c   Pallante, Pierlorenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

CBX7; HMGA1b; NF B; Osteopontin; Thyroid carcinomas

Indexed keywords

BMI1 PROTEIN; CHEMOKINE; CHROMOBOX HOMOLOG 7 PROTEIN; HIGH MOBILITY GROUP A1B PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOPONTIN; PROTEIN; RNA; UNCLASSIFIED DRUG; CBX7 PROTEIN, HUMAN; SPP1 PROTEIN, HUMAN;

ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL INVASION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENETIC CODE; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; PHENOTYPE; PROMOTER REGION; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SPP1 GENE; THYROID CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; BINDING SITE; CARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; THYROID TUMOR; TUMOR CELL LINE;

BINDING SITES; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION; HEK293 CELLS; HMGA1B PROTEIN; HUMANS; NF-KAPPA B; OSTEOPONTIN; POLYCOMB REPRESSIVE COMPLEX 1; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84923308811     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2777     Document Type: Article

References (35)

1. Otte AP, Kwaks TH. Gene repression by Polycomb group protein complexes: a distinct complex for every occasion?. Curr Opin Genet Dev. 2003; 13:448-454.
2. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6:846-856.
3. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell. 2005; 20:845-854.
4. Wang S, Robertson GP, Zhu J. A novel human homologue of Drosophila polycomblike gene is up-regulated in multiple cancers. Gene. 2004; 343:69-78.
5. Shinjo K, Yamashita Y, Yamamoto E, Akatsuka S, Uno N, Kamiya A, Niimi K, Sakaguchi Y, Nagasaka T, Takahashi T, Shibata K, Kajiyama H, Kikkawa F, Toyokuni S. Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. Int J Cancer. 2014; 135:308-318.
6. Bernard D, Martinez-Leal JF, Rizzo S, Martinez D, Hudson D, Visakorpi T, Peters G, Carnero A, Beach D, Gil J. CBX7 controls the growth of normal and tumorderived prostate cells by repressing the Ink4a/Arf locus. Oncogene. 2005; 24:5543-5551.
7. Gil J, Bernard D, Martinez D, Beach D. Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol. 2004; 6:67-72.
8. Scott CL, Gil J, Hernando E, Teruya-Feldstein J, Narita M, Martinez D, Visakorpi T, Mu D, Cordon-Cardo C, Peters G, Beach D, Lowe SW. Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A. 2007; 104:5389-5394.
9. Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F, Iaccarino A, Russo M, Pierantoni GM, Leone V, Sacchetti S, Troncone G, Santoro M, Fusco A. Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res. 2008; 68:6770-6778.
10. Pallante P, Terracciano L, Carafa V, Schneider S, Zlobec I, Lugli A, Bianco M, Ferraro A, Sacchetti S, Troncone G, Fusco A, Tornillo L. The loss of the CBX7 gene expression represents an adverse prognostic marker for survival of colon carcinoma patients. Eur J Cancer. 2010; 46:2304-2313.
11. Mansueto G, Forzati F, Ferraro A, Pallante P, Bianco M, Esposito F, Iaccarino A, Troncone G, Fusco A. Identification of a New Pathway for Tumor Progression: MicroRNA-8b Up-Regulation and CBX7 Down-Regulation by HMGA Protein. Genes Cancer. 2010; 1:210-224.
12. Karamitopoulou E, Pallante P, Zlobec I, Tornillo L, Carafa V, Schaffner T, Borner M, Diamantis I, Esposito F, Brunner T, Zimmermann A, Federico A, Terracciano L, Fusco A. Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer. 2010; 46:1438-1444.
13. Forzati F, Federico A, Pallante P, Abbate A, Esposito F, Malapelle U, Sepe R, Palma G, Troncone G, Scarfo M, Arra C, Fedele M, Fusco A. CBX7 is a tumor suppressor in mice and humans. J Clin Invest. 2012; 122:612-623.
14. Federico A, Pallante P, Bianco M, Ferraro A, Esposito F, Monti M, Cozzolino M, Keller S, Fedele M, Leone V, Troncone G, Chiariotti L, Pucci P, Fusco A. Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. Cancer Res. 2009; 69:7079-7087.
15. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007; 7:899-910.
16. Pegoraro S, Ros G, Piazza S, Sommaggio R, Ciani Y, Rosato A, Sgarra R, Del Sal G, Manfioletti G. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget. 2013; 4:1293-1308.
17. Esposito F, De Martino M, Petti MG, Forzati F, Tornincasa M, Federico A, Arra C, Pierantoni GM, Fusco A. HMGA1 pseudogenes as candidate protooncogenic competitive endogenous RNAs. Oncotarget. 2014; 5:8341-8354.
18. Puca F, Colamaio M, Federico A, Gemei M, Tosti N, Bastos AU, Del Vecchio L, Pece S, Battista S, Fusco A. HMGA1 silencing restores normal stem cell characteristics in colon cancer stem cells by increasing p3 levels. Oncotarget. 2014; 5:3234-3245.
19. Pallante P, Sepe R, Federico A, Forzati F, Bianco M, Fusco A. CBX7 Modulates the Expression of Genes Critical for Cancer Progression. PLoS One. 2014; 9:e98295.
20. Matusan K, Dordevic G, Stipic D, Mozetic V, Lucin K. Osteopontin expression correlates with prognostic variables and survival in clear cell renal cell carcinoma. J Surg Oncol. 2006; 94:325-331.
21. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 2007; 102:859-868.
22. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR, Janssen KP. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer. 2007; 121:1717-1723.
23. Berge G, Pettersen S, Grotterod I, Bettum IJ, Boye K, Maelsmo GM. Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis. Int J Cancer. 2011; 129:780-790.
24. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab. 2005; 90:5270-5278.
25. Lewis H, Kaszubska W, DeLamarter JF, Whelan J. Cooperativity between two NF-kappa B complexes, mediated by high-mobility-group protein I(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol Cell Biol. 1994; 14:5701-5709.
26. Visconti R, Cerutti J, Battista S, Fedele M, Trapasso F, Zeki K, Miano MP, de Nigris F, Casalino L, Curcio F, Santoro M, Fusco A. Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene. 1997; 15:1987-1994.
27. Pacifico F, Mauro C, Barone C, Crescenzi E, Mellone S, Monaco M, Chiappetta G, Terrazzano G, Liguoro D, Vito P, Consiglio E, Formisano S, Leonardi A. Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas. J Biol Chem. 2004; 279:54610-54619.
28. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006; 7:667-677.
29. Whitcomb SJ, Basu A, Allis CD, Bernstein E. Polycomb Group proteins: an evolutionary perspective. Trends Genet. 2007; 23:494-502.
30. Zhang H, Guo M, Chen JH, Wang Z, Du XF, Liu PX, Li WH. Osteopontin Knockdown Inhibits alpha,beta Integrin- Induced Cell Migration and Invasion and Promotes Apoptosis of Breast Cancer Cells by Inducing Autophagy and Inactivating the PI3K/Akt/mTOR Pathway. Cell Physiol Biochem. 2014; 33:991-1002.
31. Liaw L, Lindner V, Schwartz SM, Chambers AF, Giachelli CM. Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res. 1995; 77:665-672.
32. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem. 2002; 85:728-736.
33. Federico A, Forzati F, Esposito F, Arra C, Palma G, Barbieri A, Palmieri D, Fedele M, Pierantoni GM, De Martino I, Fusco A. Hmga1/Hmga2 double knock-out mice display a "superpygmy" phenotype. Biol Open. 3:372-378.
34. Pierantoni GM, Fedele M, Pentimalli F, Benvenuto G, Pero R, Viglietto G, Santoro M, Chiariotti L, Fusco A. High mobility group I (Y) proteins bind HIPK2, a serinethreonine kinase protein which inhibits cell growth. Oncogene. 2001; 20:6132-6141.
35. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402-408.